Arsenal Biosciences

Arsenal Biosciences, Inc. (ArsenalBio) is a clinical-stage programmable cell therapy company headquartered in South San Francisco, California, that discovers and develops next-generation autologous T cell therapies for solid tumors. The company describes a "full-stack" R&D engine intended to generate multifunctional T cell medicines, combining computational design with cell engineering, clinical development and manufacturing capabilities in one organization.

Its pipeline targets ovarian, kidney and prostate cancers, plus additional solid tumor programs co-developed with Bristol-Myers Squibb. Lead candidate AB-1015 is being tested in patients with treatment-resistant ovarian tumors, and a second candidate, AB-2100, entered a Phase 1/2 trial in clear-cell renal cell carcinoma with U.S. FDA Fast Track designation; the first patient in that trial was dosed in April 2024. The company also runs an AB-4000 series under its collaboration with Bristol Myers Squibb and has a research collaboration with Roche.

ArsenalBio was spun out of the Parker Institute for Cancer Immunotherapy and, as of September 2024, reported roughly 265 employees across two San Francisco Bay Area sites and about $700 million secured in combined equity funding and partnership dollars.

Founding story

ArsenalBio originated as a spin-out of the Parker Institute for Cancer Immunotherapy, founded by Sean Parker's institute ecosystem, and debuted publicly in October 2019. Co-founders include Ken Drazan, MD, who serves as Chairman and CEO and previously was President and Chief Business Officer of GRAIL and founder/board director of Verb Surgical, and W. Nicholas Haining, BM BCh, a physician-scientist and immunologist who is Chief Scientific Officer.

Business model

ArsenalBio develops proprietary autologous T cell therapy candidates in-house and supplements internal funding with pharmaceutical partnerships; it has industry collaborations with Bristol Myers Squibb (including the AB-4000 series, structured with milestones) and Roche, alongside venture and crossover equity financing.

No product revenue is described; funding comes from equity financings and partnership dollars, with roughly $700 million secured in combined equity and partnership funding as of September 2024.

Traction

Two product candidates in human testing (AB-1015 in ovarian cancer and AB-2100 in ccRCC, the latter with FDA Fast Track designation and first patient dosed in April 2024), a milestone achieved with Bristol Myers Squibb on the AB-4000 series, two industry partnerships (Bristol Myers Squibb and Roche), about 265 employees, and roughly $700 million in cumulative equity and partnership funding.

Latest developments

In September 2024 ArsenalBio closed a $325 million oversubscribed Series C to fund clinical development, manufacturing scale-up and platform innovation. Its second candidate, AB-2100, entered a Phase 1/2 trial in clear-cell renal cell carcinoma with Fast Track designation, dosing its first patient in April 2024; initial results for the ovarian candidate AB-1015 were expected around the end of 2024. The company also announced a milestone achievement with Bristol Myers Squibb for the AB-4000 series under an ongoing multi-program collaboration, and was scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference. A prostate cancer program could reach human testing within a few years, and management indicated another collaboration might be disclosed.